Suzuki Takahiro
Department of Hematology, School of Medicine, Kitasato University.
Rinsho Ketsueki. 2023;64(6):474-481. doi: 10.11406/rinketsu.64.474.
Aplastic anemia (AA) is a non-neoplastic bone marrow failure syndrome caused by the destruction of hematopoietic stem and progenitor cells by the immune system. However, in some cases of AA, a small number of specific clones with gene mutations are observed without clinical manifestations. Cases with mutated PIG-A, BCOR/BCORL1, or HLA class I allele clones respond better to immunosuppressive therapies (ISTs). Cases with MDS-related clones, such as DNMT3A or ASXL1 mutations, are at a higher risk for secondary MDS. In this review, I will focus on the clonal hematopoiesis (CH) in AA and discuss its clinical significance, including its impact on disease boundaries and transition. I will also discuss the pathophysiology and diagnosis of hypoplastic MDS, a type of MDS that responds to ISTs.
再生障碍性贫血(AA)是一种非肿瘤性骨髓衰竭综合征,由免疫系统破坏造血干细胞和祖细胞引起。然而,在某些AA病例中,观察到少数具有基因突变的特定克隆,且无临床表现。携带PIG-A、BCOR/BCORL1或HLA I类等位基因克隆突变的病例对免疫抑制治疗(IST)反应更好。携带与骨髓增生异常综合征(MDS)相关克隆的病例,如DNMT3A或ASXL1突变,发生继发性MDS的风险更高。在本综述中,我将重点关注AA中的克隆性造血(CH),并讨论其临床意义,包括其对疾病界限和转变的影响。我还将讨论低增生性MDS的病理生理学和诊断,低增生性MDS是一种对IST有反应的MDS类型。